(CAH) Cardinal Health - Ratings and Ratios
Pharmaceuticals, Medical Devices, Surgical Products, Laboratory Supplies
CAH EPS (Earnings per Share)
CAH Revenue
Description: CAH Cardinal Health September 29, 2025
Cardinal Health Inc. (NYSE: CAH) is a U.S.–based, globally-active healthcare services and products firm that operates through two primary segments: Pharmaceutical and Specialty Solutions, and Global Medical Products and Distribution. The company delivers customized supply-chain and clinical solutions to hospitals, health systems, pharmacies, ambulatory surgery centers, clinical labs, physician offices, and home-care patients, while also manufacturing and distributing its own branded medical, surgical, and laboratory devices.
Beyond wholesale distribution of branded, generic, and specialty pharmaceuticals, Cardinal Health provides a suite of value-added services-including specialty drug management for manufacturers, pharmacy-management solutions for hospitals, and repackaging of generic and OTC products. It also produces and supplies a broad portfolio of medical consumables (e.g., exam gloves, needles, compression garments, wound-care items) and assembles sterile and non-sterile procedure kits, leveraging integrated technology to optimize direct-ship logistics.
Key performance indicators from the most recent fiscal year (2023) show revenue of roughly $181 billion, with the Pharmaceutical and Specialty Solutions segment contributing about 55 % of total sales and delivering a modest operating margin of 3.5 % after a year-over-year decline driven by drug-price concessions and inventory adjustments. The Global Medical Products and Distribution segment posted a 4-year compound annual growth rate (CAGR) of ≈ 2.8 % in volume, reflecting continued demand for consumables amid the shift toward outpatient and ambulatory care settings.
Sector-level drivers that materially affect Cardinal Health’s outlook include an aging U.S. population increasing overall drug utilization, the acceleration of outpatient procedures that boosts demand for medical-device consumables, and ongoing regulatory pressure on drug pricing that compresses margins for distributors. Additionally, supply-chain digitization and automation are becoming competitive differentiators, with firms that can provide real-time inventory visibility and predictive analytics gaining market share.
For a deeper, data-driven assessment of how these dynamics translate into valuation metrics, you may find it useful to explore the analytical tools available on ValueRay.
CAH Stock Overview
| Market Cap in USD | 45,105m |
| Sub-Industry | Health Care Distributors |
| IPO / Inception | 1987-12-31 |
CAH Stock Ratings
| Growth Rating | 95.1% |
| Fundamental | 73.5% |
| Dividend Rating | 42.8% |
| Return 12m vs S&P 500 | 46.9% |
| Analyst Rating | 4.12 of 5 |
CAH Dividends
| Dividend Yield 12m | 1.07% |
| Yield on Cost 5y | 4.86% |
| Annual Growth 5y | -6.01% |
| Payout Consistency | 95.2% |
| Payout Ratio | 22.8% |
CAH Growth Ratios
| Growth Correlation 3m | 64.4% |
| Growth Correlation 12m | 86.7% |
| Growth Correlation 5y | 95.5% |
| CAGR 5y | 36.86% |
| CAGR/Max DD 3y (Calmar Ratio) | 2.03 |
| CAGR/Mean DD 3y (Pain Ratio) | 7.96 |
| Sharpe Ratio 12m | 2.24 |
| Alpha | 61.24 |
| Beta | 0.718 |
| Volatility | 77.85% |
| Current Volume | 4080.7k |
| Average Volume 20d | 1776.8k |
| Stop Loss | 185 (-3%) |
| Signal | -0.24 |
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income (1.59b TTM) > 0 and > 6% of Revenue (6% = 14.06b TTM) |
| FCFTA 0.08 (>2.0%) and ΔFCFTA 5.57pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -0.74% (prev -0.79%; Δ 0.05pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.09 (>3.0%) and CFO 5.02b > Net Income 1.59b (YES >=105%, WARN >=100%) |
| Net Debt (4.44b) to EBITDA (3.26b) ratio: 1.36 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.96 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (239.0m) change vs 12m ago -2.45% (target <= -2.0% for YES) |
| Gross Margin 3.66% (prev 3.36%; Δ 0.30pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 476.8% (prev 520.9%; Δ -44.11pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 9.21 (EBITDA TTM 3.26b / Interest Expense TTM 263.0m) >= 6 (WARN >= 3) |
Altman Z'' 0.09
| (A) -0.03 = (Total Current Assets 38.54b - Total Current Liabilities 40.27b) / Total Assets 55.23b |
| (B) 0.02 = Retained Earnings (Balance) 1.12b / Total Assets 55.23b |
| (C) 0.05 = EBIT TTM 2.42b / Avg Total Assets 49.14b |
| (D) -0.10 = Book Value of Equity -5.62b / Total Liabilities 57.96b |
| Total Rating: 0.09 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 73.52
| 1. Piotroski 5.0pt = 0.0 |
| 2. FCF Yield 8.99% = 4.49 |
| 3. FCF Margin 1.90% = 0.48 |
| 4. Debt/Equity -3.31 = -2.50 |
| 5. Debt/Ebitda 1.36 = 1.20 |
| 6. ROIC - WACC (= 29.21)% = 12.50 |
| 7. RoE -55.72% = -2.50 |
| 8. Rev. Trend 72.64% = 5.45 |
| 9. EPS Trend 88.01% = 4.40 |
What is the price of CAH shares?
Over the past week, the price has changed by +17.84%, over one month by +21.94%, over three months by +23.30% and over the past year by +78.32%.
Is Cardinal Health a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CAH is around 246.66 USD . This means that CAH is currently undervalued and has a potential upside of +29.3% (Margin of Safety).
Is CAH a buy, sell or hold?
- Strong Buy: 9
- Buy: 2
- Hold: 5
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the CAH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 189.4 | -0.7% |
| Analysts Target Price | 189.4 | -0.7% |
| ValueRay Target Price | 272.1 | 42.7% |
CAH Fundamental Data Overview November 01, 2025
P/E Trailing = 28.6335
P/E Forward = 16.9205
P/S = 0.2026
P/B = 16.0657
P/EG = 1.6278
Beta = 0.718
Revenue TTM = 234.31b USD
EBIT TTM = 2.42b USD
EBITDA TTM = 3.26b USD
Long Term Debt = 7.98b USD (from longTermDebt, last fiscal year)
Short Term Debt = 52.0m USD (from shortTermDebt, last quarter)
Debt = 9.03b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.44b USD (from netDebt column, last quarter)
Enterprise Value = 49.54b USD (45.11b + Debt 9.03b - CCE 4.59b)
Interest Coverage Ratio = 9.21 (Ebit TTM 2.42b / Interest Expense TTM 263.0m)
FCF Yield = 8.99% (FCF TTM 4.45b / Enterprise Value 49.54b)
FCF Margin = 1.90% (FCF TTM 4.45b / Revenue TTM 234.31b)
Net Margin = 0.68% (Net Income TTM 1.59b / Revenue TTM 234.31b)
Gross Margin = 3.66% ((Revenue TTM 234.31b - Cost of Revenue TTM 225.72b) / Revenue TTM)
Gross Margin QoQ = 3.62% (prev 3.66%)
Tobins Q-Ratio = 0.90 (Enterprise Value 49.54b / Total Assets 55.23b)
Interest Expense / Debt = 0.89% (Interest Expense 80.0m / Debt 9.03b)
Taxrate = 24.08% (144.0m / 598.0m)
NOPAT = 1.84b (EBIT 2.42b * (1 - 24.08%))
Current Ratio = 0.96 (Total Current Assets 38.54b / Total Current Liabilities 40.27b)
Debt / Equity = -3.31 (negative equity) (Debt 9.03b / totalStockholderEquity, last quarter -2.73b)
Debt / EBITDA = 1.36 (Net Debt 4.44b / EBITDA 3.26b)
Debt / FCF = 1.00 (Net Debt 4.44b / FCF TTM 4.45b)
Total Stockholder Equity = -2.86b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.89% (Net Income 1.59b / Total Assets 55.23b)
RoE = -55.72% (negative equity) (Net Income TTM 1.59b / Total Stockholder Equity -2.86b)
RoCE = 47.34% (EBIT 2.42b / Capital Employed (Equity -2.86b + L.T.Debt 7.98b))
RoIC = 36.54% (NOPAT 1.84b / Invested Capital 5.03b)
WACC = 7.33% (E(45.11b)/V(54.14b) * Re(8.66%) + D(9.03b)/V(54.14b) * Rd(0.89%) * (1-Tc(0.24)))
Discount Rate = 8.66% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.43%
[DCF Debug] Terminal Value 76.59% ; FCFE base≈3.10b ; Y1≈3.21b ; Y5≈3.64b
Fair Price DCF = 240.1 (DCF Value 57.04b / Shares Outstanding 237.6m; 5y FCF grow 3.48% → 3.0% )
EPS Correlation: 88.01 | EPS CAGR: 27.05% | SUE: 4.0 | # QB: 1
Revenue Correlation: 72.64 | Revenue CAGR: 8.25% | SUE: 4.0 | # QB: 1
Additional Sources for CAH Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle